Carmen Carriles, P. Jiménez Fonseca, M. Sánchez Cánovas, P. Pimentel, Alberto Carmona Bayonas, T. García García, M. Carbajales Álvarez, Ana Lozano Blázquez
Introduction Our aim was to assess efficacy and safety and prognostic factors associated with TAS-102 in clinical practice.
Method Retrospective, multicenter, and observational study including patients with advanced refractory colorectal cancer who started TAS-102 between March 2016 and August 2018. The primary end point was overall survival (OS). Secondary end points included progression-free survival, toxicity and analyze prognostic factors present at the beginning of TAS-102.
Result 84 patients were evaluable. The median OS was 8.30 (95% CI 6.23–9.87) months and PFS was 2.62 (95% CI 2.36–3.05) months. In multivariate analysis, ECOG 0 and reduced dose combined with more cycles were associated with better prognosis. Patients with an ECOG > 0 had worse prognosis (HR 3.34, 95% CI 1.09–10.27, p = 0.035). 95.2% experienced some type of adverse effect and 45.2% had grade ≥ 3 toxicities.
Conclusion Results suggest reconsidering TAS-102 in patients with ECOG > 0, something that should be investigated in prospective randomized clinical trials.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados